• Bufalin Workflows for Cancer Mechanism Studies

  2026-09-21

  Build reproducible Bufalin assays around apoptosis, AP-1 signaling, and target-protein degradation rather than relying on viability data alone. This workflow connects concentration control, STK33-focused validation, and practical troubleshooting for triple-negative breast cancer research and related oncology models.

• Baricitinib: JAK1/2 Workflows for Inflammation

  2026-09-21

  Baricitinib (LY3009104) gives researchers a selective pharmacologic route to test JAK1/2-dependent cytokine signaling, from IL-6–STAT3 assays to preclinical arthritis models. This guide translates spatial proteomics findings in primary sclerosing cholangitis into practical dosing, controls, troubleshooting, and pathway-validation workflows.

• Perospirone: From Receptors to Assay Design

  2026-09-20

  Perospirone (SM-9018 free base) is a receptor-active neuropharmacology tool with a newly defined vascular ion-channel dimension. This guide translates its receptor affinities, Kv1.5 findings, and physicochemical properties into practical assay-design decisions.

• Forskolin for cAMP-Resolved Stem Cell Assays

  2026-09-19

  Forskolin is a direct adenylate cyclase activator for dissecting cAMP-dependent biology. This article develops an assay-centered strategy linking Forskolin perturbation to stem cell differentiation, neuroendocrine secretion, and translational interpretation without confusing cAMP modulation with lineage specification.

• Formononetin Protects Neurons During Oxaliplatin Therapy

  2026-09-18

  A 2026 NeuroToxicology study identifies formononetin as a potential neuroprotective agent that reduces oxaliplatin-induced oxidative stress and neuronal apoptosis through Nrf2/HO-1 activation. Its key translational advance is that it preserved oxaliplatin and paclitaxel anticancer activity in cell models, unlike the antioxidant comparator N-acetylcysteine.

• SIS3 Smad3 Inhibitor: OA Assay Workflow

  2026-09-18

  SIS3 offers a selective way to interrogate Smad3-dependent transcription without directly suppressing Smad2 phosphorylation. This practical workflow translates evidence from early osteoarthritis models into reproducible assay design for cartilage, fibrosis research, and related TGF-β studies.

• Pam3CSK4 TFA: TLR1/2 Activation Workflows

  2026-09-17

  Learn how to use Pam3CSK4 TFA as a defined TLR1/2 agonist for cytokine profiling, donor-to-donor immune phenotyping, and translational inflammation studies. The workflow emphasizes controlled stimulation, IL-17A-focused readouts, reproducible stock handling, and practical troubleshooting.

• JAK Inhibitors and Endothelial Vascular Effects

  2026-09-17

  This comparative study shows that JAK inhibitors can suppress inflammatory cytokine release in endothelial cells without uniformly correcting adhesion, coagulation, or cell-survival abnormalities. Its main practical contribution is a concentration- and compound-specific framework for interpreting vascular effects during inflammatory disease research.

• PF-562271 HCl: FAK Signaling Beyond the Tumor

  2026-09-16

  A translational framework for using PF-562271 HCl to connect FAK/Pyk2 signaling, metastatic niche biology, and circulating phagocytic polyploid giant cancer macrophages in cancer research.

• CX-4945: Practical CK2 Inhibition Workflows

  2026-09-16

  CX-4945 (Silmitasertib) provides a practical way to connect CK2 activity with apoptosis, cell-cycle control, stemness, and chemoresistance. This guide translates lung-cancer findings into matched cell models, target-engagement assays, and troubleshooting strategies for reproducible CK2 inhibition experiments.

• Baricitinib for JAK1/2-STAT3 Assay Design

  2026-09-15

  Baricitinib (LY3009104) provides a selective pharmacological test of JAK1/2 dependence in IL-6- and IL-23-responsive systems. This workflow translates spatial PD-L1–IL-6 observations in primary sclerosing cholangitis into controlled cell, co-culture, and ex vivo experiments while separating pathway evidence from disease-model inference.

• Sphingosine-1-phosphate: Practical Research Workflows

  2026-09-15

  Build more informative S1P experiments by pairing dose–time studies with receptor, kinase, and apoptosis readouts. This guide translates vascular, neuronal, and cell-survival applications into practical workflows while emphasizing fresh preparation, vehicle controls, and receptor-subtype validation.

• Necrosulfonamide for MLKL Necroptosis Assays

  2026-09-14

  Necrosulfonamide helps separate upstream stress signaling from terminal MLKL-driven membrane rupture in necroptosis assays. This guide translates recent cardiac ischemia–reperfusion findings into practical workflows for dose selection, p-MLKL localization, calcium–mitochondrial readouts, and troubleshooting.

• AMPK–JAK2/STAT3 Signaling in Obesity-Related Asthma

  2026-09-14

  The reference study identifies reduced AMPK activity and M1 macrophage polarization as linked features of obesity-related asthma, and places the JAK2/STAT3 pathway downstream of AMPK in this inflammatory context. Its combined mouse and RAW264.7-cell experiments support AMPK activation as a mechanistically informed direction for studying airway inflammation, while leaving clinical translation and reagent-specific effects to future work.

• Okadaic acid (A4540): PP1/PP2A Workflow Guide

  2026-09-13

  Okadaic acid (A4540) provides a controlled way to reduce PP2A activity at low nanomolar concentrations and affect PP1 at higher concentrations, supporting phosphorylation and apoptosis experiments. It is best used in defined biochemical or cell-based studies with matched solvent controls, not as a broad-spectrum phosphatase inhibitor or as a direct substitute for cell-specific potency data.

8359 records 1/558 page Next 12345 下5页 Last page